Metastatic Prostate Cancer clinical trials

Explore recruiting metastatic prostate cancer clinical trials.

Recruiting metastatic prostate cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Metastatic Prostate Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase I/II Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6621, a T Cell-engaging Antibody That Targets STEAP2, CD3, and CD8 in Adult Participants With Metastatic Prostate Cancer (ACTIVATED-4-PC)

Belgium, Spain, Poland, Italy, Netherlands

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A First-In-Human, phase I/IIa, open-label trial assessing safety, tolerability, and feasibility of repeated administrations of a novel autologous tumor-infiltrating lymphocyte-based immunotherapy in patients with metastatic colorectal or prostate cancer

Germany

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Molecular theranostics for metastatic prostate cancer: PSMA, FAPI, or both?

Finland

Therapeutic exploratory (Phase II) EU CTIS Study details

A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination with New Hormonal Agents in Patients with Metastatic Prostate Cancer (PETRANHA)

Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Phase I study of 225Ac-PSMA I&T in prostate cancer

Netherlands

Human Pharmacology (Phase I)- Bioequivalence Study EU CTIS Study details

ReaLuP : an open label, single arm phase IIb study of re-treatment with [177Lu]Lu-PSMA in men with metastatic castration resistance prostate cancer

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Metastatic Prostate Cancer trials by city

Metastatic Prostate Cancer in Toronto Metastatic Prostate Cancer in Vancouver Metastatic Prostate Cancer in Montreal Metastatic Prostate Cancer in Calgary Metastatic Prostate Cancer in Edmonton Metastatic Prostate Cancer in Ottawa Metastatic Prostate Cancer in Winnipeg Metastatic Prostate Cancer in Quebec City Metastatic Prostate Cancer in Hamilton Metastatic Prostate Cancer in Kitchener Metastatic Prostate Cancer in London Metastatic Prostate Cancer in Halifax Metastatic Prostate Cancer in New York Metastatic Prostate Cancer in Los Angeles Metastatic Prostate Cancer in Chicago Metastatic Prostate Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease